vs

Side-by-side financial comparison of AMCON DISTRIBUTING CO (DIT) and Insulet Corporation (PODD). Click either name above to swap in a different company.

Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $730.1M, roughly 1.1× AMCON DISTRIBUTING CO). Insulet Corporation runs the higher net margin — 13.0% vs 0.1%, a 12.9% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 2.6%). Insulet Corporation produced more free cash flow last quarter ($48.2M vs $-12.4M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 10.1%).

AMCON Distributing Co is a US-based consumer product distribution firm offering groceries, beverages, health and beauty products, tobacco, and general merchandise. It primarily serves independent convenience stores, grocery retailers, pharmacies, and small retail outlets across the continental United States.

An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.

DIT vs PODD — Head-to-Head

Bigger by revenue
PODD
PODD
1.1× larger
PODD
$783.7M
$730.1M
DIT
Growing faster (revenue YoY)
PODD
PODD
+28.5% gap
PODD
31.2%
2.6%
DIT
Higher net margin
PODD
PODD
12.9% more per $
PODD
13.0%
0.1%
DIT
More free cash flow
PODD
PODD
$60.6M more FCF
PODD
$48.2M
$-12.4M
DIT
Faster 2-yr revenue CAGR
PODD
PODD
Annualised
PODD
33.2%
10.1%
DIT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DIT
DIT
PODD
PODD
Revenue
$730.1M
$783.7M
Net Profit
$793.0K
$101.6M
Gross Margin
6.6%
72.6%
Operating Margin
0.5%
18.7%
Net Margin
0.1%
13.0%
Revenue YoY
2.6%
31.2%
Net Profit YoY
127.6%
0.9%
EPS (diluted)
$1.28
$1.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DIT
DIT
PODD
PODD
Q4 25
$730.1M
$783.7M
Q3 25
$746.3M
$706.3M
Q2 25
$739.6M
$649.1M
Q1 25
$619.5M
$569.0M
Q4 24
$711.3M
$597.5M
Q3 24
$746.3M
$543.9M
Q2 24
$717.9M
$488.5M
Q1 24
$601.9M
$441.7M
Net Profit
DIT
DIT
PODD
PODD
Q4 25
$793.0K
$101.6M
Q3 25
$491.7K
$87.6M
Q2 25
$1.3M
$22.5M
Q1 25
$-1.6M
$35.4M
Q4 24
$348.4K
$100.7M
Q3 24
$1.2M
$77.5M
Q2 24
$1.5M
$188.6M
Q1 24
$539.5K
$51.5M
Gross Margin
DIT
DIT
PODD
PODD
Q4 25
6.6%
72.6%
Q3 25
6.5%
72.2%
Q2 25
6.7%
69.7%
Q1 25
6.9%
71.9%
Q4 24
6.6%
72.1%
Q3 24
6.5%
69.3%
Q2 24
6.7%
67.7%
Q1 24
7.0%
69.5%
Operating Margin
DIT
DIT
PODD
PODD
Q4 25
0.5%
18.7%
Q3 25
0.5%
16.7%
Q2 25
0.7%
18.7%
Q1 25
0.1%
15.6%
Q4 24
0.5%
18.3%
Q3 24
0.7%
16.2%
Q2 24
0.8%
11.2%
Q1 24
0.6%
12.9%
Net Margin
DIT
DIT
PODD
PODD
Q4 25
0.1%
13.0%
Q3 25
0.1%
12.4%
Q2 25
0.2%
3.5%
Q1 25
-0.3%
6.2%
Q4 24
0.0%
16.9%
Q3 24
0.2%
14.2%
Q2 24
0.2%
38.6%
Q1 24
0.1%
11.7%
EPS (diluted)
DIT
DIT
PODD
PODD
Q4 25
$1.28
$1.42
Q3 25
$0.80
$1.24
Q2 25
$2.13
$0.32
Q1 25
$-2.58
$0.50
Q4 24
$0.57
$1.38
Q3 24
$2.02
$1.08
Q2 24
$2.46
$2.59
Q1 24
$0.89
$0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DIT
DIT
PODD
PODD
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$930.8M
Stockholders' EquityBook value
$114.1M
$1.5B
Total Assets
$378.7M
$3.2B
Debt / EquityLower = less leverage
0.61×

8-quarter trend — quarters aligned by calendar period.

Total Debt
DIT
DIT
PODD
PODD
Q4 25
$930.8M
Q3 25
$16.5M
$934.9M
Q2 25
$939.0M
Q1 25
$1.6B
Q4 24
$1.3B
Q3 24
$21.8M
$1.4B
Q2 24
$23.3M
$1.4B
Q1 24
$20.5M
$1.4B
Stockholders' Equity
DIT
DIT
PODD
PODD
Q4 25
$114.1M
$1.5B
Q3 25
$113.1M
$1.4B
Q2 25
$113.2M
$1.5B
Q1 25
$111.4M
$1.3B
Q4 24
$112.4M
$1.2B
Q3 24
$111.7M
$1.1B
Q2 24
$110.0M
$998.4M
Q1 24
$108.0M
$790.7M
Total Assets
DIT
DIT
PODD
PODD
Q4 25
$378.7M
$3.2B
Q3 25
$391.1M
$3.0B
Q2 25
$393.9M
$3.5B
Q1 25
$392.0M
$3.5B
Q4 24
$404.7M
$3.1B
Q3 24
$374.1M
$3.0B
Q2 24
$400.6M
$2.9B
Q1 24
$336.2M
$2.6B
Debt / Equity
DIT
DIT
PODD
PODD
Q4 25
0.61×
Q3 25
0.15×
0.68×
Q2 25
0.64×
Q1 25
1.21×
Q4 24
1.07×
Q3 24
0.19×
1.21×
Q2 24
0.21×
1.36×
Q1 24
0.19×
1.72×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DIT
DIT
PODD
PODD
Operating Cash FlowLast quarter
$-11.7M
$183.3M
Free Cash FlowOCF − Capex
$-12.4M
$48.2M
FCF MarginFCF / Revenue
-1.7%
6.2%
Capex IntensityCapex / Revenue
0.1%
17.2%
Cash ConversionOCF / Net Profit
-14.75×
1.80×
TTM Free Cash FlowTrailing 4 quarters
$40.6M
$377.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DIT
DIT
PODD
PODD
Q4 25
$-11.7M
$183.3M
Q3 25
$31.1M
$125.7M
Q2 25
$-7.0M
$196.5M
Q1 25
$34.4M
$63.8M
Q4 24
$-39.9M
$147.7M
Q3 24
$41.0M
$98.5M
Q2 24
$-26.9M
$96.5M
Q1 24
$48.8M
$87.6M
Free Cash Flow
DIT
DIT
PODD
PODD
Q4 25
$-12.4M
$48.2M
Q3 25
$30.4M
$100.1M
Q2 25
$-8.8M
$177.9M
Q1 25
$31.4M
$51.5M
Q4 24
$-43.3M
$94.1M
Q3 24
$37.4M
$71.8M
Q2 24
$-32.6M
$74.0M
Q1 24
$41.6M
$65.5M
FCF Margin
DIT
DIT
PODD
PODD
Q4 25
-1.7%
6.2%
Q3 25
4.1%
14.2%
Q2 25
-1.2%
27.4%
Q1 25
5.1%
9.1%
Q4 24
-6.1%
15.7%
Q3 24
5.0%
13.2%
Q2 24
-4.5%
15.1%
Q1 24
6.9%
14.8%
Capex Intensity
DIT
DIT
PODD
PODD
Q4 25
0.1%
17.2%
Q3 25
0.1%
3.6%
Q2 25
0.2%
2.9%
Q1 25
0.5%
2.2%
Q4 24
0.5%
9.0%
Q3 24
0.5%
4.9%
Q2 24
0.8%
4.6%
Q1 24
1.2%
5.0%
Cash Conversion
DIT
DIT
PODD
PODD
Q4 25
-14.75×
1.80×
Q3 25
63.32×
1.43×
Q2 25
-5.33×
8.73×
Q1 25
1.80×
Q4 24
-114.43×
1.47×
Q3 24
33.16×
1.27×
Q2 24
-18.05×
0.51×
Q1 24
90.37×
1.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DIT
DIT

Cigarettes$446.5M61%
Tobacco$143.7M20%
Tobacco Food Service And Other$82.3M11%
Confectionery$46.7M6%
Retail Segment$10.8M1%

PODD
PODD

U.S.Omnipod$567.8M72%
International Omnipod$214.0M27%
Drug Delivery$1.9M0%

Related Comparisons